#China #Hong Kong #Immunotherapy #Akeso #AK150

Akeso's Groundbreaking Trispecific Antibody AK150 Enters Clinical Trials

In a major advancement for cancer immunotherapy, Akeso, Inc. (9926.HK) has announced that its innovative trispecific antibody, AK150, has secured Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) to commence clinical trials. This announcement marks a significant milestone not only for Akeso but for the broader landscape of cancer treatment, as AK150 is the world's first trispecific antibody targeting ILT2, ILT4, and CSF1R.

Understanding the Role of AK150

AK150 is engineered utilizing Akeso's advanced AI-driven drug discovery technology, coupled with its proprietary Tetrabody platform. This trispecific antibody is specifically designed to target and modulate the immune response against advanced solid tumors, which often present challenging immunosuppressive environments. The tumor types that AK150 primarily focuses on include non-small cell lung cancer, hepatocellular carcinoma, pancreatic cancer, and certain resistant forms of breast cancer.

Current therapies targeting individual or dual aspects of macrophage-related pathways often fail to comprehensively dismantle the immunosuppression ingrained in the tumor microenvironment. This creates an urgent demand for more innovative, multi-target therapies like AK150 that can synergistically remodel immune responses and improve treatment efficacy in suboptimal conditions, particularly in diseases categorized as “cold tumors.”

Mechanism of Action

AK150's strength lies in its ability to simultaneously block three crucial immunomodulatory targets: ILT2, ILT4, and CSF1R. By doing so, it enables a coordinated immune response that boosts both innate and adaptive immunity. This tri-target approach not only has the potential to enhance responses to “hot tumors” but also aims to convert “cold tumors” into a responsive state, thus improving their susceptibility to immunotherapy.

The antibody operates by:
1. Depleting Immunosuppressive Myeloid Cells: The blockade of CSF1R impairs the survival of myeloid cells that contribute to tumor evasion.
2. Releasing Immune Cell Function: Blocking ILT2 and ILT4 mitigates the suppression of remaining myeloid cells, bolstering the activity of innate immune components, including Natural Killer (NK) cells and CD8+ T cells.
3. Synergistic Activity: The combined action of AK150 on these pathways promotes a multi-dimensional relief of the immunosuppressed state, addressing the key challenges rooted in solid tumor drug development.

Preclinical Validation and Future Outlook

Preclinical studies have demonstrated AK150's potential through dose-dependent tumor inhibition in various models, indicating its therapeutic promise as a transformative option in solid tumor treatments. This clinical trial will pave the way for further investigation into AK150's efficacy and safety profile in human subjects.

About Akeso

Founded in 2012, Akeso has positioned itself as a leading biopharmaceutical enterprise dedicated to developing innovative biological therapies. They leverage their state-of-the-art Tetrabody platform and an array of other therapeutic modalities to create novel solutions across a broad spectrum of diseases, including cancer and autoimmune disorders. With over 50 drug candidates in its pipeline, 27 of which are already in clinical trials, Akeso is advancing its goal of making first-in-class biological medicines accessible to patients globally.

Akeso remains committed to integrating advanced biopharmaceutical innovation to combat critical healthcare challenges, continuously generating value for patients and stakeholders in the international health landscape.